Mark S. Livingston, the Chief Financial Officer of Progyny, Inc., executed a sale of the company’s common stock totaling $211,012 on May 20, 2026. The specific details of this transaction involved divesting 8,275 shares at an agreed price of $25.50 per share.
It is noted that these shares were sold pursuant to a Rule 10b5-1 trading plan, a mechanism Mr. Livingston initiated on August 15, 2025. At the time of the sale, the common stock was trading at $24.69 per share, which was slightly below the price achieved by the CFO in this transaction.
Despite this recent activity, analysis suggests that Progyny may be undervalued. According to InvestingPro Fair Value calculations, the company's shares are positioned among stocks listed on the platform’s Most Undervalued list.
Following the sale of these shares, Mr. Livingston currently maintains a direct holding of 79,063 shares of Progyny common stock. The overall valuation of the company stands at $1.94 billion. Furthermore, financial metrics indicate that the company trades with a PEG ratio of 0.85 and has reported profitability over the preceding twelve months.
Recent Corporate Performance Highlights
The recent operational reporting from Progyny Inc. paints a picture of strong performance, as the firm’s first-quarter results surpassed expectations set by Wall Street analysts. The company reported adjusted earnings per share of $0.50 for the quarter. This figure represented a notable beat when compared to the analyst consensus estimate of $0.26.
Revenue achieved a record high of $328.5 million. This total was slightly higher than the consensus estimate of $326.57 million and marked a 1.4% increase year-over-year (YoY). When factoring out revenue from a major client that did not renew in 2025, the company’s growth rate stood at 12.2% compared to the previous year.
Analyst Reactions and Future Outlook
The positive financial developments prompted several industry analysts to adjust their outlook on Progyny. Specifically, Canaccord Genuity upgraded Progyny’s stock rating from Hold to Buy. This upgrade was attributed by the firm to the company's consistent track record of exceeding quarterly estimates for both revenue and adjusted EBITDA over six consecutive quarters.
In parallel, Citizens also raised its price target for Progyny. The new price target set by Citizens is $31, accompanied by a Market Outperform rating. Additionally, Citizens increased its estimate for the company’s 2026 EBITDA to $239 million. These varied developments collectively signal an optimistic view from external analysts regarding Progyny's financial health and potential trajectory of growth.
Key Takeaways
The analysis of the provided data highlights several key points concerning the company's current standing:
- Financial Strength: Progyny reported strong first-quarter figures, including record revenue and adjusted earnings per share that beat market expectations.
- Analyst Confidence: Multiple financial institutions issued positive reports, including stock rating upgrades and increased price targets, citing sustained performance.
- Valuation Indicators: The company's valuation metrics, such as the PEG ratio of 0.85, combined with third-party analysis suggesting undervaluation, point toward potential market interest.
The data also allows for examination of specific risks and uncertainties:
- Client Dependency Risk: One piece of information noted is that revenue growth was calculated after excluding a major client who did not renew in 2025, which could imply sensitivity to key accounts.
- Insider Selling Activity: The recent sale by the CFO, Mark S. Livingston, represents an instance of insider selling, which investors often monitor for signals regarding internal confidence.
- Market Fluctuation Risk: The stock's trading price on the day of the transaction ($24.69) was slightly below the amount received from the sale ($25.50), but general market movements and daily fluctuations remain a factor.
These developments, spanning insider transactions, strong quarterly reporting, and positive analyst revisions, provide a detailed view into Progyny's current operational environment and perceived growth potential within the sector.